新诺威：关于控股子公司帕妥珠单抗注射液上市申请获得受理的公告

Core Viewpoint - The announcement indicates that the company's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received the acceptance notice for the marketing application of the drug Patuzumab Injection from the National Medical Products Administration [1] Group 1 - The acceptance of the marketing application is a significant step for the company in advancing its product pipeline [1] - The drug Patuzumab Injection is likely to contribute to the company's revenue growth upon successful commercialization [1]